|
1
|
Siegel R, Ma JM, Zou ZH and Jemal A:
Cancer statistics, 2014. Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Joint Committee on Cancer (AJCC),
. TNM staging system. September 6–2013, American Cancer
Society;
|
|
4
|
Tamm EP, Silverman PM, Charnsangavej C and
Evans DB: Diagnosis, staging, and surveillance of pancreatic
cancer. AJR Am J Roentgenol. 180:1311–1323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varadachary GR, Tamm EP, Abbruzzese JL,
Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB and Wolff
RA: Borderline resectable pancreatic cancer: Definitions,
management, and role of preoperative therapy. Ann Surg Oncol.
13:1035–1046. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Katz MH, Marsh R, Herman JM, Shi Q,
Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM,
et al: Borderline resectable pancreatic cancer: Need for
standardization and methods for optimal clinical trial design. Ann
Surg Oncol. 20:2787–2795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abrams RA, Lowy AM, O'Reilly EM, Wolff RA,
Picozzi VJ and Pisters PW: Combined modality treatment of
resectable and borderline resectable pancreas cancer: Expert
consensus statement. Ann Surg Oncol. 16:1751–1756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tempero MA, Malafa MP, Behrman, Benson AB
III, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B,
Engebretson A, et al: Pancreatic adenocarcinoma, version 2.2014:
Featured updates to the NCCN guidelines. J Natl Compr Canc Netw.
12:1083–1093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valls C, Andía E, Sanchez A, Fabregat J,
Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F and Jorba R:
Dual-phase helical CT of pancreatic adenocarcinoma: Assessment of
resectability before surgery. AJR Am J Roentgenol. 178:821–826.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Legmann P, Vignaux O, Dousset B, Baraza
AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier
D and Bonnin A: Pancreatic tumors: Comparison of dual-phase helical
CT and endoscopic sonography. AJR Am J Roentgenol. 170:1315–1322.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeWitt J, Devereaux B, Chriswell M,
McGreevy K, Howard T, Imperiale TF, Ciaccia D, Lane KA, Maglinte D,
Kopecky K, et al: Comparison of endoscopic ultrasonography and
multidetector computed tomography for detecting and staging
pancreatic cancer. Ann Intern Med. 141:753–763. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Michl P, Pauls S and Gress TM:
Evidence-based diagnosis and staging of pancreatic cancer. Best
Pract Res Clin Gastroenterol. 20:227–251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim R, Prithviraj G, Kothari N, Springett
G, Malafa M, Hodul P, Kim J, Yue B, Morse B and Mahipal A: PET/CT
fusion scan prevents futile laparotomy in early stage pancreatic
cancer. Clin Nucl Med. 40:e501–e505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katz MH, Fleming JB, Bhosale P,
Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW,
Vauthey JN, et al: Response of borderline resectable pancreatic
cancer to neoadjuvant therapy is not reflected by radiographic
indicators. Cancer. 118:5749–5756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferrone CR, Marchegiani G, Hong TS, Ryan
DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN,
Blaszkowsky LS, et al: Radiological and surgical implications of
neoadjuvant treatment with FOLFIRINOX for locally advanced and
borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM,
Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, et
al: Early mortality risk score: Identification of poor outcomes
following upfront surgery for resectable pancreatic cancer. J
Gastrointest Surg. 16:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tzeng CW, Balachandran A, Ahmad M, Lee JE,
Krishnan S, Wang H, Crane CH, Wolff RA, Varadhachary GR, Pisters
PW, et al: Serum carbohydrate antigen 19–9 represents a marker of
response to neoadjuvant therapy in patients with borderline
resectable pancreatic cancer. HPB (Oxford). 16:430–438. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iacobuzio-Donahue CA, Fu B, Yachida S, Luo
M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P,
et al: DPC4 gene status of the primary carcinoma correlates with
patterns of failure in patients with pancreatic cancer. J Clin
Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singh P, Wig JD, Srinivasan R and Radotra
BD: A comprehensive examination of Smad4, Smad6 and Smad7 mRNA
expression in pancreatic ductal adenocarcinoma. Indian J Cancer.
48:170–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Infante JR, Matsubayashi H, Sato N,
Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and
Goggins M: Peritumoral fibroblast SPARC expression and patient
outcome with resectable pancreatic adenocarcinoma. J Clin Oncol.
25:319–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyoshi K, Sato N, Ohuchida K, Mizumoto K
and Tanaka M: SPARC mRNA expression as a prognostic marker for
pancreatic adenocarcinoma patients. Anticancer Res. 30:867–871.
2010.PubMed/NCBI
|
|
24
|
Prenzel KL, Warnecke-Eberz U, Xi H,
Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Hölscher AH
and Schneider PM: Significant overexpression of SPARC/osteonectin
mRNA in pancreatic cancer compared to cancer of the papilla of
Vater. Oncol Rep. 15:1397–1401. 2006.PubMed/NCBI
|
|
25
|
Nagaraju GP, Dontula R, El-Rayes BF and
Lakka SS: Molecular mechanisms underlying the divergent roles of
SPARC in human carcinogenesis. Carcinogenesis. 35:967–973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Desai NP, Trieu V, Hwang LY, Wu R,
Soon-Shiong P and Gradishar WJ: Improved effectiveness of
nanoparticle albumin-bound (nab) paclitaxel versus
polysorbate-based docetaxel in multiple xenografts as a function of
HER2 and SPARC status. Anticancer Drugs. 19:899–909. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong HQ and Abbruzzese JL: Epidermal
growth factor receptor-targeted therapy for pancreatic cancer.
Semin Oncol. 29 5 Suppl 14:S31–S37. 2002. View Article : Google Scholar
|
|
28
|
Yamanaka Y, Friess H, Kobrin MS, Buchler
M, Beger HG and Korc M: Coexpression of epidermal growth factor
receptor and ligands in human pancreatic cancer is associated with
enhanced tumor aggressiveness. Anticancer Res. 13:565–569.
1993.PubMed/NCBI
|
|
29
|
Hu YC, Komorowski RA, Graewin S, Hostetter
G, Kallioniemi OP, Pitt HA and Ahrendt SA: Thymidylate synthase
expression predicts the response to 5-fluorouracil-based adjuvant
therapy in pancreatic cancer. Clin Cancer Res. 9:4165–4171.
2003.PubMed/NCBI
|
|
30
|
van der Zee JA, van Eijck CH, Hop WC, van
Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM and Ten
Hagen TL: Expression and prognostic significance of thymidylate
synthase (TS) in pancreatic head and periampullary cancer. Eur J
Surg Oncol. 38:1058–1064. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jin K, Luo G, Xiao Z, Liu Z, Liu C, Ji S,
Xu J, Liu L, Long J, Ni Q and Yu X: Noncoding RNAs as potential
biomarkers to predict the outcome in pancreatic cancer. Drug Des
Devel Ther. 9:1247–1255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ansari D, Gustafsson A and Andersson R:
Update on the management of pancreatic cancer: Surgery is not
enough. World J Gastroenterol. 21:3157–3165. 2015.PubMed/NCBI
|
|
33
|
Evans DB, Varadhachary GR, Crane CH, Sun
CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA,
et al: Preoperative gemcitabine-based chemoradiation for patients
with resectable adenocarcinoma of the pancreatic head. J Clin
Oncol. 26:3496–3502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Varadhachary GR, Wolff RA, Crane CH, Sun
CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA,
et al: Preoperative gemcitabine and cisplatin followed by
gemcitabine-based chemoradiation for resectable adenocarcinoma of
the pancreatic head. J Clin Oncol. 26:3487–3495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cho SW, Tzeng CW, Johnston WC, Cassera MA,
Newell PH, Hammill CW, Wolf RF, Aloia TA and Hansen PD: Neoadjuvant
radiation therapy and its impact on complications after
pancreaticoduodenectomy for pancreatic cancer: Analysis of the
American College of Surgeons National Surgical Quality Improvement
Program (ACS-NSQIP). HPB (Oxford). 16:350–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lind PA, Isaksson B, Almström M, Johnsson
A, Albiin N, Byström P and Permert J: Efficacy of preoperative
radiochemotherapy in patients with locally advanced pancreatic
carcinoma. Acta Oncol. 47:413–420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abbott DE, Tzeng CW, Merkow RP, Cantor SB,
Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary
GR, et al: The cost-effectiveness of neoadjuvant chemoradiation is
superior to a surgery-first approach in the treatment of pancreatic
head adenocarcinoma. Ann Surg Oncol. 20 Suppl 3:S500–S5008. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Katz MH, Pisters PW, Evans DB, Sun CC, Lee
JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, et al:
Borderline resectable pancreatic cancer: The importance of this
emerging stage of disease. J Am Coll Surg. 206:833–848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chun YS, Milestone BN, Watson JC, Cohen
SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ,
Denlinger CS, et al: Defining venous involvement in borderline
resectable pancreatic cancer. Ann Surg Oncol. 17:2832–2838. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rose JB, Rocha FG, Alseidi A, Biehl T,
Moonka R, Ryan JA, Lin B, Picozzi V and Helton S: Extended
neoadjuvant chemotherapy for borderline resectable pancreatic
cancer demonstrates promising postoperative outcomes and survival.
Ann Surg Oncol. 21:1530–1537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Takahashi H, Ohigashi H, Gotoh K,
Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M and
Ishikawa O: Preoperative gemcitabine-based chemoradiation therapy
for resectable and borderline resectable pancreatic cancer. Ann
Surg. 258:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mahaseth H, Brutcher E, Kauh J, Hawk N,
Kim S, Chen Z, Kooby DA, Maithel SK, Landry J and El-Rayes BF:
Modified FOLFIRINOX regimen with improved safety and maintained
efficacy in pancreatic adenocarcinoma. Pancreas. 42:1311–1315.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Boone BA, Steve J, Krasinskas AM, Zureikat
AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ and Bahary N:
Outcomes with FOLFIRINOX for borderline resectable and locally
unresectable pancreatic cancer. J Surg Oncol. 108:236–241. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gunturu KS, Yao X, Cong X, Thumar JR,
Hochster HS, Stein SM and Lacy J: FOLFIRINOX for locally advanced
and metastatic pancreatic cancer: Single institution retrospective
review of efficacy and toxicity. Med Oncol. 30:3612013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Peddi PF, Lubner S, McWilliams R, Tan BR,
Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, et
al: Multi-institutional experience with FOLFIRINOX in pancreatic
adenocarcinoma. JOP. 13:497–501. 2012.PubMed/NCBI
|
|
47
|
Hosein PJ, Macintyre J, Kawamura C,
Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A,
Portelance L, Merchan JR, et al: A retrospective study of
neoadjuvant FOLFIRINOX in unresectable or borderline-resectable
locally advanced pancreatic adenocarcinoma. BMC Cancer. 12:1992012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tinchon C, Hubmann E, Pichler A, Keil F,
Pichler M, Rabl H, Uggowitzer M, Jilek K, Leitner G and Bauernhofer
T: Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a
series of patients with borderline resectable pancreatic ductal
adenocarcinoma. Acta Oncol. 52:1231–1233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Christians KK, Tsai S, Mahmoud A, Ritch P,
Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB and
George B: Neoadjuvant FOLFIRINOX for borderline resectable pancreas
cancer: A new treatment paradigm? Oncologist. 19:266–274. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Faris JE, Blaszkowsky LS, McDermott S,
Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen
JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic
cancer: The Massachusetts General Hospital Cancer Center
experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
James ES, Yao X, Cong X, Li J, Hahn C,
Kaley K, Kortmansky JS, Fischbach NA, Chang BW, Salem RR, et al:
Interim analysis of a phase II study of dose-modified FOLFIRINOX
(mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic
cancer (MPC). J Clin Oncol. 32 Suppl:e152262014. View Article : Google Scholar
|
|
52
|
Hazariwala R, Landry J, El-Reyes B, et al:
Neoadjuvant FOLFIRINOX and radiation therapy improves resectability
of pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2 Suppl
1:872013.
|
|
53
|
Vasile E, de Lio N, Cappelli C, et al:
Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI
in borderline resectable or unresectable stage III pancreatic
cancer. J Clin Oncol. 15(Suppl 1): 312013.
|
|
54
|
Kharofa J, Kelly TR, Ritch PS, George B,
Wiebe LA, Thomas JP, Christians KK, Evans DP and Erickson B:
5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction
followed by chemoXRT in borderline resectable pancreatic cancer. J
Clin Oncol. 30 Suppl:e146132012.
|
|
55
|
Lowery MA, Yu KH, Adel NG, Apollo AJ,
Boyar MS, Caron P, Ilson D, Segal NH, Janjigian YY, Janjigian DR,
et al: Activity of front-line FOLFIRINOX (FFX) in stage III/IV
pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer
Center (MSKCC). J Clin Oncol. 30 Suppl:40572012.
|
|
56
|
Blazer M, Wu C, Goldberg RM, Phillips G,
Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J,
Ellison EC, et al: Neoadjuvant modified (m) FOLFIRINOX for locally
advanced unresectable (LAPC) and borderline resectable (BRPC)
adenocarcinoma of the pancreas. Ann Surg Oncol. 22:1153–1159. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nanda RH, El-Rayes B, Maithel SK and
Landry J: Neoadjuvant modified FOLFIRINOX and chemoradiation
therapy for locally advanced pancreatic cancer improves
resectability. J Surg Oncol. 111:1028–1034. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Paniccia A, Edil BH, Schulick RD, Byers
JT, Meguid C, Gajdos C and McCarter MD: Neoadjuvant FOLFIRINOX
application in borderline resectable pancreatic adenocarcinoma: A
retrospective cohort study. Medicine (Baltimore). 93:e1982014.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mellon EA, Hoffe SE, Springett GM, Frakes
JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD and Shridhar R:
Long-term outcomes of induction chemotherapy and neoadjuvant
stereotactic body radiotherapy for borderline resectable and
locally advanced pancreatic adenocarcinoma. Acta Oncol. 54:979–985.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu
M, Ghilardi M, Lonati V, Aitini E and Barni S: Gruppo Italiano per
lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD):
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or
unresectable pancreatic cancer: A meta-analytical review of
published studies. Pancreas. 44:515–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Oettle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Katz MH, Shi Q, Ahmad SA, Herman JM, de
Marsh RW, Collisson EA, Schwartz LH, Martin RC, Conway WC, Truty M,
et al: Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by
chemoradiation (CRT) for borderline resectable (BLR) pancreatic
cancer (PDAC): Initial results from Alliance Trial A021101. J Clin
Oncol. 33(Suppl): abstr 4008. 2015.
|
|
64
|
Pancreatic Resectability in Cancers With
Known Limited Extension (PRICKLE)-A Single-centre Phase 2a Study of
Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally
Advanced Pancreatic Cancer. ClinicalTrials.gov Identifier:
NCT02124369. 2017.
|
|
65
|
Breslin TM, Hess KR, Harbison DB, Jean ME,
Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH,
et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the
pancreas: Treatment variables and survival duration. Ann Surg
Oncol. 8:123–132. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ishikawa O, Ohhigashi H, Teshima T,
Chatani M, Inoue T, Tanaka S, Kitamura T, Wada A, Sasaki Y, Imaoka
S, et al: Clinical and histopathological appraisal of preoperative
irradiation for adenocarcinoma of the pancreatoduodenal region. J
Surg Oncol. 40:143–151. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Washington K, Berlin J and Branton P:
Protocol for the examination of specimens from patients with
carcinoma of the exocrine pancreas: Protocol applies to all
epithelial tumors of the exocrine pancreas. Endocrine tumors and
tumors of the ampulla of Vater are not included Northfield, IL:
College of American Pathologists; 2010
|
|
68
|
Oshima M, Okano K, Muraki S, Haba R, Maeba
T, Suzuki Y and Yachida S: Immunohistochemically detected
expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4)
strongly predicts survival in patients with resectable pancreatic
cancer. Ann Surg. 258:336–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pendurthi TK, Cooper HS, Young NA, et al:
Histopathologic effects of preoperative chemoradiotheraoy on
pancreatic carcinoma. Gastroenterology. 110:A1410. 1996.
|
|
70
|
White RR, Xie HB, Gottfried MR, Czito BG,
Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS,
et al: Significance of histological response to preoperative
chemoradiotherapy for pancreatic cancer. Ann Surg Oncol.
12:214–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sasson AR, Wetherington RW, Hoffman JP,
Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF and
Eisenberg BL: Neoadjuvant chemoradiotherapy for adenocarcinoma of
the pancreas: Analysis of histopathology and outcome. Int J
Gastrointest Cancer. 34:121–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hoffman JP, Weese JL, Solin LJ, Engstrom
P, Agarwal P, Barber LW, Guttmann MC, Litwin S, Salazar H and
Eisenberg BL: A pilot study of preoperative chemoradiation for
patients with localized adenocarcinoma of the pancreas. Am J Surg.
169:71–78. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Aschele C, Cionini L, Lonardi S, Pinto C,
Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti
P, et al: Primary tumor response to preoperative chemoradiation
with or without oxaliplatin in locally advanced rectal cancer:
Pathologic results of the STAR-01 randomized phase III trial. J
Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
García-Aguilar J, de Anda E Hernandez,
Sirivongs P, Lee SH, Madoff RD and Rothenberger DA: A pathologic
complete response to preoperative chemoradiation is associated with
lower local recurrence and improved survival in rectal cancer
patients treated by mesorectal excision. Dis Colon Rectum.
46:298–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Martin ST, Heneghan HM and Winter DC:
Systematic review and meta-analysis of outcomes following
pathological complete response to neoadjuvant chemoradiotherapy for
rectal cancer. Br J Surg. 99:918–928. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Maas M, Nelemans PJ, Valentini V, Das P,
Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R,
Haustermans K, et al: Long-term outcome in patients with a
pathological complete response after chemoradiation for rectal
cancer: A pooled analysis of individual patient data. Lancet Oncol.
11:835–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Meredith KL, Weber JM, Turaga KK, Siegel
EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S and
Karl R: Pathologic response after neoadjuvant therapy is the major
determinant of survival in patients with esophageal cancer. Ann
Surg Oncol. 17:1159–1167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pasini F, de Manzoni G, Zanoni A,
Grandinetti A, Capirci C, Pavarana M, Tomezzoli A, Rubello D and
Cordiano C: Neoadjuvant therapy with weekly docetaxel and
cisplatin, 5-fluorouracil continuous infusion, and concurrent
radiotherapy in patients with locally advanced esophageal cancer
produced a high percentage of long-lasting pathological complete
response: A phase 2 study. Cancer. 119:939–945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Rohatgi P, Swisher SG, Correa AM, Wu TT,
Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA and
Ajani JA: Characterization of pathologic complete response after
preoperative chemoradiotherapy in carcinoma of the esophagus and
outcome after pathologic complete response. Cancer. 104:2365–2372.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Berger AC, Farma J, Scott WJ, Freedman G,
Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to
neoadjuvant chemoradiotherapy in esophageal carcinoma is associated
with significantly improved survival. J Clin Oncol. 23:4330–4337.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Vallböhmer D, Hölscher AH, DeMeester S,
DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W,
Bollschweiler E and Hofstetter W: A multicenter study of survival
after neoadjuvant radiotherapy/chemotherapy and esophagectomy for
ypT0N0M0R0 esophageal cancer. Ann Surg. 252:744–749. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Symmans WF, Peintinger F, Hatzis C, Rajan
R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et
al: Measurement of residual breast cancer burden to predict
survival after neoadjuvant chemotherapy. J Clin Oncol.
25:4414–4422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Adams S, Chakravarthy AB, Donach M, Spicer
D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F,
et al: Preoperative concurrent paclitaxel-radiation in locally
advanced breast cancer: Pathologic response correlates with
five-year overall survival. Breast Cancer Res Treat. 124:723–732.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sherman WH, Chu K, Chabot J, Allendorf J,
Schrope BA, Hecht E, Jin B, Leung D, Remotti H, Addeo G, et al:
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by
gemcitabine and capecitabine/radiation therapy and surgery in
locally advanced, unresectable pancreatic adenocarcinoma. Cancer.
121:673–680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Boone BA, Steve J, Zenati MS, Hogg ME,
Singhi AD, Bartlett DL, Zureikat AH, Bahary N and Zeh HJ III: Serum
CA 19–9 response to neoadjuvant therapy is associated with outcome
in pancreatic adenocarcinoma. Ann Surg Oncol. 21:4351–4358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rajagopalan MS, Heron DE, Wegner RE, Zeh
HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn
AE and Burton SA: Pathologic response with neoadjuvant chemotherapy
and stereotactic body radiotherapy for borderline resectable and
locally-advanced pancreatic cancer. Radiat Oncol. 8:2542013.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lee JL, Kim SC, Kim JH, Lee SS, Kim TW,
Park DH, Seo DW, Lee SK, Kim MH, Kim JH, et al: Prospective
efficacy and safety study of neoadjuvant gemcitabine with
capecitabine combination chemotherapy for borderline-resectable or
unresectable locally advanced pancreatic adenocarcinoma. Surgery.
152:851–862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE,
Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, et al:
Pathologic complete response to neoadjuvant therapy in patients
with pancreatic ductal adenocarcinoma is associated with a better
prognosis. Ann Diagn Pathol. 16:29–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chatterjee D, Katz MH, Rashid A,
Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN,
Crane C, et al: Histologic grading of the extent of residual
carcinoma following neoadjuvant chemoradiation in pancreatic ductal
adenocarcinoma: A predictor for patient outcome. Cancer.
118:3182–3190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Barugola G, Partelli S, Crippa S, Capelli
P, D'Onofrio M, Pederzoli P and Falconi M: Outcomes after resection
of locally advanced or borderline resectable pancreatic cancer
after neoadjuvant therapy. Am J Surg. 203:132–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Le Scodan R, Mornex F, Partensky C,
Mercier C, Valette PJ, Ychou M, Bibeau F and Scoazec JY: Histologic
assessment of treatment effect of preoperative chemoradiation in
patients presenting with resectable pancreatic adenocarcinoma.
Cancer Radiother. 15:97–105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Turrini O, Ychou M, Moureau-Zabotto L,
Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR and
Viret F: Neoadjuvant docetaxel-based chemoradiation for resectable
adenocarcinoma of the pancreas: New neoadjuvant regimen was safe
and provided an interesting pathologic response. Eur J Surg Oncol.
36:987–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Magnin V, Moutardier V, Giovannini MH,
Lelong B, Giovannini M, Viret F, Monges G, Bardou VJ, Alzieu C and
Delpero JR: Neoadjuvant preoperative chemoradiation in patients
with pancreatic cancer. Int J Radiat Oncol Biol Phys. 55:1300–1304.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wanebo HJ, Glicksman AS, Vezeridis MP,
Clark J, Tibbetts L, Koness RJ and Levy A: Preoperative
chemotherapy, radiotherapy, and surgical resection of locally
advanced pancreatic cancer. Arch Surg. 135:81–88. 2000. View Article : Google Scholar : PubMed/NCBI
|
